🇺🇸 FDA
Patent

US 11938174

Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders

granted A61KA61K35/16A61K38/55

Quick answer

US patent 11938174 (Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders) held by Takeda Pharmaceutical Company Limited expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K35/16, A61K38/55, A61K38/57, A61K39/3955